Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA progress, and launch potential by 2026.

Anito-cel’s Phase 3 trial results are expected by yearend 2024, with a possible BLA submission in 2025, entering a $34.4 billion market. Despite a premium valuation, ...

Philippine indie game developer Anino Entertainment has today announced the launch of Anito: Defend a Land Enraged. The adventure role-playing game, which was recently confirmed as a finalist in ...

Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its therapy candidate anito-cel for the treatment of multiple myeloma. The ...

Anito will be coming out in the UK, Belgium, the Netherlands, Luxembourg, Norway, Sweden, Denmark, Finland, and Russia. We're also looking for a distributor in the US and other territories.

Anito: Defend A Land Enraged The first Filipino-made PC game is finally here!. After two years of waiting, Philippine indie game developer Anino Entertainment is proud to launch its pioneering ...

The process of turning a patient’s immune cells into a living drug isn’t always successful, but Arcellx said anito-cell was successfully manufactured for 99% of patients in its studies. Kite ...

Anito-cel is a BCMA CAR T that utilizes a novel binder (or CAR) known as the D-Domain. Its small size (8kDa) facilitates high T-cell transduction and expression, resulting in more CAR positive ...

Anito: Defend a Land Enraged Mini-Review at Gameshark In the main, a recommending write-up for developer Anino's isometric perspective genre-crossing title ...

Anito-cel is a BCMA CAR T that utilizes a novel binder (or CAR) known as the D-Domain. Its small size (8kDa) facilitates high T-cell transduction and expression, resulting in more CAR positive ...